Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19935129 | 0.85 | — | — | |
| SCHEMBL22959617 | 0.82 | — | — | |
| SCHEMBL10202604 | 0.82 | — | — | |
| SCHEMBL21933618 | 0.82 | — | — | |
| SCHEMBL17927979 | 0.81 | CYP19A1 (0.33) | — | |
| SCHEMBL7155825 | 0.79 | — | — | |
| SCHEMBL24449624 | 0.78 | THRA (0.39) | THRATHRB | |
| SCHEMBL178343 | 0.78 | THRA (0.39) | THRATHRB | |
| SCHEMBL24448837 | 0.78 | THRA (0.39) | THRATHRB | |
| SCHEMBL24449476 | 0.76 | THRA (0.38) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033817-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-02-03 | — | — | US | disclosed |
| US-11174481-B2 | Targeting ligands | Arrowhead Pharmaceuticals, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20190256849-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033817-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | THRA 1160/4885THRB 833/4885 |
| US-20190256849-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | THRA 1160/4885THRB 833/4885 |
| US-11174481-B2 | Targeting ligands | FABP1, SNRPE, HAVCR2 | THRA 1160/4885THRB 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.